Specific determination and identification of cross-linked fibrin degradation products in patients under thrombolytic therapy for myocardial infarction.
We have demonstrated that the specific determination and identification of plasma FbDP alone is not sufficient to follow the effectiveness of thrombolytic therapy. Some patients who received an intravenous infusion of rt-PA for myocardial infarction had very high plasma FbDP levels, although no recanalization was observed angiographically. Since in many cases the FbDP levels increased after recanalization, it is assumed that rethrombosis may occur during and after t-PA treatment.
D000911:Antibodies, Monoclonal; D000918:Antibody Specificity; D003101:Collodion; D004591:Electrophoresis, Polyacrylamide Gel; D005338:Fibrin Fibrinogen Degradation Products / Q000032:analysis*; D005343:Fibrinolytic Agents / Q000494:pharmacology / Q000627:therapeutic use*; D006801:Humans; D007262:Infusions, Intravenous; D008722:Methods; D009203:Myocardial Infarction / Q000097:blood / Q000188:drug therapy*; D011487:Protein Conformation; D011994:Recombinant Proteins / Q000008:administration & dosage / Q000627:therapeutic use; D012967:Sodium Dodecyl Sulfate; D010959:Tissue Plasminogen Activator / Q000008:administration & dosage / Q000627:therapeutic use
D000911:Antibodies, Monoclonal; D005338:Fibrin Fibrinogen Degradation Products; D005343:Fibrinolytic Agents; D011994:Recombinant Proteins; D012967:Sodium Dodecyl Sulfate; D003101:Collodion; D010959:Tissue Plasminogen Activator